Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

Imatinib (IM) treatment efficacy in 116 chronic myeloid leukemia (CML) patients in different studies was analyzed. Patient group was non‑selective with prospective enrollment. The study was based on real‑time patient’s register allows to treatment quality control due to clinical results. Cytogenetic...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. K. Golenkov, L. L. Vysotskaya, E. V. Trifonova, T. A. Mitina, T. D. Lutskaya, E. V. Kataeva, G. A. Dudina, Yu. B. Chernykh, I. V. Buravtsova, A. N. Gurov, R. V. Gorenkov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Онкогематология
Subjects:	chronic myeloid leukemia imatinib organizational technologies treatment quality control mean daily dose cytogenetic response overall survival
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/49
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01)

Profile of pediatric chronic myeloid leukemia in the era of imatinib: A study from South India
by: Catherene Bernard, et al.
Published: (2019-01-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Report of chronic myeloid leukemia in chronic phase from Ashirwad Hematology Centre, Mumbai, 2002-2009
by: M B Agarwal, et al.
Published: (2013-01-01)

Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia chronic phase on frontline imatinib
by: Ranga Raman Ganta, et al.
Published: (2017-01-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Imatinib mesylate resistance and mutations: An Indian experience
by: Shweta Srivastava, et al.
Published: (2013-01-01)

Long-Term Safety and Efficacy of Imatinib in Chronic Myeloid Leukemia: Real-World Evidence from a Single-Center Study
by: İsmail Can Kendir, et al.
Published: (2025-06-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
by: Michiels S, et al.
Published: (2024-09-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients
by: Maedeh Khosravi, et al.
Published: (2021-05-01)

Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development
by: Irina Badralexi, et al.
Published: (2024-12-01)

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
by: Hongpeng Duan, et al.
Published: (2024-12-01)

Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009
by: Senthil Rajappa, et al.
Published: (2013-01-01)

Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with cronic myeloid leukemia treated with imatinib
by: Bojan Labachevski, et al.
Published: (2024-12-01)

Priapism in chronic myeloid leukemia: Meeting at the crossroads and heading in different directions
by: Kundan Mishra, et al.
Published: (2020-01-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Report of patients with chronic myeloid leukemia, from hematology clinic, Ahmedabad, Gujarat 2000-2010 at 1 st myelostone meeting: Indian evidence of chronic myelogenous leukemia
by: Uday R Deotare, et al.
Published: (2013-01-01)

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming
by: Lan Yang, et al.
Published: (2025-07-01)

The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad
by: Sandip A Shah
Published: (2013-01-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

Cytogenetics and Molecular Abnormalities in Pediatric Patients with Acute Myeloid Leukemia in a Referral Center in Tehran, Iran
by: Mahshid Heidary Sadegh, et al.
Published: (2025-01-01)

Infant acute myeloid leukemia: insights into the biology and therapy
by: Xiaoli Chen, et al.
Published: (2024-12-01)

Therapeutic drug monitoring for imatinib: Current status and Indian experience
by: Brijesh Arora, et al.
Published: (2013-01-01)

Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years
by: Rajesh P Dikshit, et al.
Published: (2011-01-01)

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years
by: Puligundla Krishna Chaitanya, et al.
Published: (2017-01-01)

Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010
by: Pravas Mishra, et al.
Published: (2013-01-01)

Genetic Mutations in Acute Myeloid Leukemia
by: OV Blau
Published: (2016-07-01)

Demographic and clinical characteristics of chronic myeloid leukemia patients: A study on confined populations of Southern India
by: Manjula Gorre, et al.
Published: (2019-01-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice
by: AG Turkina, et al.
Published: (2017-07-01)

Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib
by: Ikhlas Khammas, et al.
Published: (2025-06-01)